Shots:

• BioNTech and Fosun collaborated to supply 10M doses of their BNT162 mRNA-based vaccine candidate against COVID-19 to Hong Kong SAR and Macao SAR- once approved
• Fosun Pharma has signed the Letter of Intent with Jacobson for contemplated distribution of 10M doses of a vaccine targeting COVID-19 in the Chinese market
• On Mar 13- 2020- the companies collaborated to jointly develop and commercialize the vaccine in Mainland China- Hong Kong- and Macau SAR and the Taiwan region. The P-I study of BNT162b1 has been initiated in China  and enrolled 144 participants

­ Ref: BioNTech | Image: StraitTimes